dc.contributor.author |
Ortiz-Zúñiga, Ángel Michael |
dc.contributor.author |
Rodriguez-Gómez, Octavio |
dc.contributor.author |
Hernández, Cristina |
dc.contributor.author |
Rodrigo, Adrian |
dc.contributor.author |
Jamilis, Laura |
dc.contributor.author |
Campo, Laura |
dc.contributor.author |
Alegret, Montserrat |
dc.contributor.author |
Boada, Mercè |
dc.contributor.author |
Ciudin, Andreea |
dc.contributor.author |
Simó Canonge, Rafael |
dc.contributor.author |
Universitat Autònoma de Barcelona |
dc.date |
2020 |
dc.identifier |
https://ddd.uab.cat/record/233406 |
dc.identifier |
urn:10.3390/jcm9092726 |
dc.identifier |
urn:oai:ddd.uab.cat:233406 |
dc.identifier |
urn:articleid:20770383v9n9p2726 |
dc.identifier |
urn:pmid:32847012 |
dc.identifier |
urn:pmcid:PMC7565958 |
dc.identifier |
urn:pmc-uid:7565958 |
dc.identifier |
urn:oai:pubmedcentral.nih.gov:7565958 |
dc.format |
application/pdf |
dc.language |
eng |
dc.publisher |
|
dc.relation |
Journal of clinical medicine ; Vol. 9 Núm. 9 (2020), p. 2726 |
dc.rights |
open access |
dc.rights |
Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, fins i tot amb finalitats comercials, sempre i quan es reconegui l'autoria de l'obra original. |
dc.rights |
https://creativecommons.org/licenses/by/4.0/ |
dc.subject |
Type 2 diabetes |
dc.subject |
Mild cognitive impairment |
dc.subject |
Alzheimer's disease |
dc.title |
Clinical Applicability of the Specific Risk Score of Dementia in Type 2 Diabetes in the Identification of Patients with Early Cognitive Impairment : results of the MOPEAD Study in Spain |
dc.type |
Article |
dc.description.abstract |
Altres ajuts: This research was funded by the European Innovative Medicines Initiative (IMI2) Project-grant number 115985. |
dc.description.abstract |
Introduction: Although the Diabetes Specific Dementia Risk Score (DSDRS) was proposed for predicting risk of dementia at 10 years, its usefulness as a screening tool is unknown. For this purpose, the European consortium MOPEAD included the DSDRS within the specific strategy for screening of cognitive impairment in type 2 diabetes (T2D) patients attended in a third-level hospital. Material and Methods: T2D patients > 65 years, without known cognitive impairment, attended in a third-level hospital, were evaluated. As per MOPEAD protocol, patients with MMSE ≤ 27 or DSDRS ≥ 7 were referred to the memory clinic for complete neuropsychological assessment. Results: 112 T2D patients were recruited. A total of 82 fulfilled the criteria for referral to the memory unit (43 of them declined referral: 48.8% for associated comorbidities, 37.2% lack of interest, 13.95% lack of social support). At the Fundació ACE's Memory Clinic, 34 cases (87.2%) of mild cognitive impairment (MCI) and 3 cases (7.7%) of dementia were diagnosed. The predictive value of DSDRS ≥ 7 as a screening tool of cognitive impairment was AUROC = 0.739, p 0.024, CI 95% (0.609-0.825). Conclusions: We found a high prevalence of unknown cognitive impairment in TD2 patients who attended a third-level hospital. The DSDRS was found to be a useful screening tool. The presence of associated comorbidities was the main factor of declining referral. |